CagriSema (cagrilintide + semaglutide) half-life & pharmacokinetics

Reported half-life

Both components engineered for once-weekly subcutaneous dosing. Cagrilintide half-life ~180 hours (~7.5 days) through fatty-acid acylation; semaglutide half-life ~168 hours (~7 days) through fatty-acid acylation and Aib substitution. Combined weekly injection.

The half-life and pharmacokinetic profile of CagriSema (cagrilintide + semaglutide) reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (Phase III clinical trial route; not licensed)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Fixed-dose combination amylin analogue + GLP-1 receptor agonist; Phase III clinical-development unlicensed compound.

Mechanism context

Half-life interpretation depends on the underlying mechanism. CagriSema (cagrilintide + semaglutide) acts as follows:

CagriSema pairs two mechanistically distinct appetite-suppressing peptides in a single weekly injection: cagrilintide (a long-acting amylin analogue engaging the calcitonin-receptor family and specifically the amylin receptor complex CTR + RAMP) and semaglutide (the licensed GLP-1 receptor agonist). The pharmacological rationale is complementary rather than redundant — amylin and GLP-1 act through distinct receptor systems in overlapping but non-identical central nervous system circuits regulating appetite and satiety.

See the full CagriSema (cagrilintide + semaglutide) research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.